Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook, 2030

The worldwide Pharmaceutical Contract Development and Manufacturing Organization (CDMO) market is witnessing considerable expansion, driven by heightened investments in pharmaceutical research and development (R&D), the growing need for innovative therapies, and the strategic transition of pharmaceutical firms towards outsourcing to improve operational efficiency and control costs. In 2023, the market was estimated at roughly USD 146. 0 billion and is anticipated to attain USD 235. 5 billion by 2030, indicating a compound annual growth rate (CAGR) of 7. 2% from 2024 to 2030. A primary element fueling this expansion is the increasing complexity of pharmaceutical products, such as biologics and cell and gene therapies, which require specialized manufacturing capabilities that CDMOs are adequately equipped to deliver. Furthermore, the increase in pharmaceutical R&D investments is broadening drug portfolios, thus amplifying the demand for CDMO services. For instance, in 2022, F. HoffmannLa Roche raised its R&D expenditures to USD 14. 7 billion from USD 13. 3 billion in the preceding year, while Merck and Co. designated USD 13. 5 billion to R&D during the same timeframe. The market is divided into two main product categories: Active Pharmaceutical Ingredients (APIs) and drug products. In 2023, the API segment led the market, representing 81. 2% of the overall revenue. This supremacy is linked to competitive drug development and a rising demand for comprehensive CDMO services. Progress in API manufacturing, the growth of the biopharmaceutical sector, and an increasing elderly population further enhance this segment's development.

Global pharmaceutical CDMO market will reach $289.2 billion by 2030, growing by 6.9% annually over 2020-2030. The application range of the market is varied, with oncology emerging as the dominant segment in 2023, accounting for 21. 82% of the overall revenue. The rising global prevalence of cancer, coupled with considerable R&D investments and the appetite for innovative oncology drugs and biologics, propels this segment's significance. Numerous recent developments highlight the dynamic nature of the CDMO market. For example, CVC Capital Partners is looking to divest its 60% share in the Italian pharmaceutical outsourcing firm Genetic Group, targeting a valuation of approximately €700 million. This action underscores the increasing interest and investment in the CDMO sector, reflecting its strong growth potential. The global Pharmaceutical CDMO market is on a strong growth path, driven by rising R&D investments, the complexity of new therapies, and the strategic outsourcing by pharmaceutical firms to improve efficiency and concentrate on core strengths. With technological advancements and the growing range of services provided by CDMOs, the market is set for ongoing growth, presenting substantial opportunities for stakeholders throughout the pharmaceutical value chain.

North America, especially the United States, stands out as one of the top regions in the CDMO market owing to its robust pharmaceutical sector, significant RandD investments, and sophisticated regulatory structure. The U. S. is home to some of the largest pharmaceutical firms, including Pfizer, Merck, and Johnson and Johnson, which increasingly depend on CDMOs for drug development and production. The presence of wellestablished CDMOs like Catalent, Lonza, and Thermo Fisher Scientific further enhances North America’s status in the market. Europe also commands a notable share in the CDMO market, spurred by nations like Germany, Switzerland, and the United Kingdom. Germany is recognized for its strong pharmaceutical manufacturing foundation and innovation in biotechnology, while Switzerland houses significant pharmaceutical leaders like Roche and Novartis, which invest heavily in outsourcing. The U. K. has a vital role in drug development, especially within the biotech field, thereby escalating the demand for CDMO offerings. Asia Pacific is the most rapidly expanding region in the CDMO market, with China and India rising as major contributors due to their costefficient manufacturing capabilities, skilled workforce, and growing pharmaceutical sectors. China has quickly advanced its biopharmaceutical industry, while India continues to serve as a global center for generic drug production, drawing significant CDMO investments. Japan and South Korea also play notable roles in the market, with strong pharmaceutical RandD and developed manufacturing capabilities. These prominent regions propel the global CDMO market through innovation, regulatory progress, and strategic collaborations, guaranteeing the sector's sustained growth and competitiveness.

The worldwide CDMO market is categorized into the Pharmaceutical Industry and the Biopharmaceutical Industry. The pharmaceutical sector leads due to the growing need for smallmolecule drugs and costeffective outsourcing options. The biopharmaceutical industry is experiencing swift growth, propelled by the increasing demand for biologics, gene therapies, and monoclonal antibodies. More companies are outsourcing biologics production to CDMOs that have specialized knowledge in cell culture, fermentation, and recombinant DNA technology. The growth of biosimilars and personalized medicine further stimulates this segment’s expansion, with companies making investments in scalable and compliant manufacturing capabilities to address the escalating global demand. The Pharmaceutical Contract Manufacturing Organization (CMO) sector is classified into Active Pharmaceutical Ingredients (API) and Finished Dosage Formulations (FDF). The API segment is divided into Branded API Manufacturing and Generic API Manufacturing, driven by the increasing demand for generics and economical production methods. The FDF segment is categorized into Solid Dosage, Oral Liquids, Parenteral/Injectables, and Other FDFs, with injectables gaining popularity due to the growth in biologics and targeted therapies. Secondary Packaging services are also vital, ensuring adherence to regulatory standards while improving drug stability and patient safety.

The Pharmaceutical Contract Research Organization (CRO) segment is split into various subcategories, such as Preclinical Development, Phase IIV Trials, Laboratory Services, Consulting, and Data Management Services. As clinical trials become more complicated, pharmaceutical companies increasingly depend on CROs to accelerate drug development and assure regulatory compliance. Preclinical and earlyphase trials concentrate on safety evaluations, while Phase II and III trials confirm efficacy and largescale effectiveness. Phase IV trials involve monitoring after market release. Laboratory and data management services are essential for conducting bioanalytical studies, managing regulatory submissions, and facilitating seamless trial execution. The CDMO market addresses various therapeutic areas, such as Infectious Diseases, Oncology, Metabolic Disorders, Cardiovascular Disorders, Central Nervous System (CNS), Pulmonary Disorders, Gastrointestinal Disorders, and Other Therapeutic Applications. Oncology leads this segment due to the heightened demand for targeted therapies, immunotherapies, and biologics. The infectious disease segment has grown, especially following COVID19, with an increase in vaccine production. Cardiovascular and metabolic disorders, including diabetes therapies, are seeing consistent demand due to rising global incidence. CNS and gastrointestinal disorders also contribute to market growth, driven by breakthroughs in neurology and microbiomefocused therapies. The CDMO market caters to Pharmaceutical and Biopharmaceutical Companies, Medical Device Companies, and Academic Institutes. Pharmaceutical and biopharmaceutical companies remain the main clients, outsourcing drug development and manufacturing to improve efficiency and lower costs. Medical device companies also partner with CDMOs for drugdevice combination products, such as inhalers and prefilled syringes. Academic institutes hold a significant role in the initial phases of drug discovery, collaborating with CDMOs for translational research and pilotscale production. As advancements in precision medicine and biologics continue to grow, CDMOs are increasingly assisting research institutions and biotech startups in bringing innovative therapies to the market.



Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Global Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

Based on Category, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Pharmaceutical Industry
Biopharmaceutical Industry

Based on Service Type, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Pharmaceutical Contract Manufacturing Organization (CMO)
• Active Pharmaceutical Ingredients (API) (further split into Branded API Manufacturing and Generic API Manufacturing)
• Finished Dosage Formulations (FDF) (further segmented into Solid Dosage, Oral Liquids, Parenteral/Injectables, Other FDFs)
• Secondary Packaging
• Pharmaceutical Contract Research Organization (CRO)
• CRO for Pre-clinical Development
• CRO for Phase I Trials
• CRO for Phase II Trials
• CRO for Phase III Trials
• CRO for Phase IV Trials
• Laboratory Services
• Consulting Services
• Data Management Services

Based on Therapeutic Application, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Infectious Diseases
• Oncology
• Metabolic Disorders
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Gastrointestinal Disorders
• Other Therapeutic Applications

Based on End User, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Academic Institutes

The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and listing out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, annual report of companies, analyzing the government generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducted trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers in regional aspects, tier aspects, age group, and gender. Once we have primary data with us we have started verifying the details obtained from secondary sources.

Intended audience
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to agriculture industry, government bodies and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.